Multi-center, double blind randomized acitvecontrolled pilot study to Evaluate the Efficacy of FEXUCLUE® 40mg(Fexuprazan hydrochloride) in the night reflux symptoms

开始日期2024-12-23

申办/合作机构-

KCT0009504

/ Recruiting临床3期IIT

Randomized Active-Controlled Trial Evaluating Fexuprazan (Fexuclue tab) for Prevention Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy After Coronary Intervention: Scientific Association of Interventional Cardiology – Fexuprazan for patients with dual antiplatelet therapy (SAINT-FEXUDAPT) trial

开始日期2024-10-24

申办/合作机构-

KCT0008892

/ RecruitingN/A

A Multi-center, Investigator Initiated Trial to Evaluate the Efficacy of FEXUCLUE®40mg(Fexuprazan hydrochloride) in Patients with Iatrogenic Gastric Ulcer After Endoscopic Submucosal Dissection

开始日期2024-07-30

申办/合作机构

Presbyterian Medical Center

100 项与盐酸非苏拉赞相关的临床结果

登录后查看更多信息

100 项与盐酸非苏拉赞相关的转化医学

登录后查看更多信息

100 项与盐酸非苏拉赞相关的专利（医药）

登录后查看更多信息

项与盐酸非苏拉赞相关的文献（医药）

2025-12-01·LUNG

Efficacy and Safety of Fexuprazan Versus Esomeprazole for Gastroesophageal Reflux Disease-Related Chronic Cough: A Randomized, Double-Blind, Active-Controlled Exploratory Trial

Article

作者: Kang, Sung-Yoon ; Kang, Min-Gyu ; Kang, Noeul ; Lee, Byung-Jae ; Jo, Eun-Jung ; Lee, Ji Ho ; Song, Woo-Jung ; Lee, Seung Eun ; Kim, Sae-Hoon ; Bahn, Joon-Woo

PURPOSE:

Potassium-competitive acid blockers (P-CABs) are a newer class of acid suppressants with convenient dosing and a rapid onset of action, while showing efficacy comparable to proton pump inhibitors (PPIs) in treating peptic symptoms of gastroesophageal reflux disease (GERD). This study aimed to assess the effect of P-CABs on GERD-related chronic cough.

METHODS:

This randomized, double-blind, active-controlled, exploratory trial evaluated adults with chronic cough (≥ 8 weeks) and a recent physician diagnosis of GERD or peptic symptoms (< 1 month). Participants were randomized (1:1) to receive either fexuprazan 40 mg or esomeprazole 40 mg (PPI) once daily for eight weeks, along with matched placebos. The primary endpoint was the change in Leicester Cough Questionnaire (LCQ) score from baseline. Secondary endpoints included changes in the cough severity Numerical Rating Scale (NRS) and Reflux Disease Questionnaire (RDQ) scores. Safety was evaluated through monitoring adverse events.

RESULTS:

Of the 190 subjects recruited, 161 met the selection criteria and were randomized, and 146 completed the trial. The participants were predominantly female (74.3%, mean age 39 ± 12 years). After 8 weeks of treatment, cough-related quality of life improved significantly, with comparable LCQ scores change between the groups (fexuprazan: 4.9 ± 4.0 vs. esomeprazole: 5.3 ± 3.8, p = 0.558). Changes in cough severity NRS and RDQ scores were also similar between the groups. Adverse events were comparable and consisted mostly of mild symptoms.

CONCLUSION:

These findings support the potential of P-CABs as a promising alternative to PPIs for patients with chronic cough requiring acid-suppressive therapy.

2025-07-01·BIOMEDICINE & PHARMACOTHERAPY

Restoration of intestinal barrier function by fexuprazan, a potassium-competitive acid blocker, in Caco-2 cells and its higher gastrointestinal distribution in rats

Article

作者: Baek, Yeon-Ju ; Choi, Min-Koo ; Lim, Kwon-Jo ; Song, Im-Sook ; Park, Joon Seok ; Kim, Ji Duck ; Lee, Jihoon ; Jeon, Ji-Hyeon

This study aimed to investigate the efficacy of fexuprazan in restoring intestinal barrier function in comparison with other potassium-competitive acid blockers (P-CABs) and esomeprazole. The effect of fexuprazan on trans-epithelial electrical resistance (TEER) value, mRNA and protein expression of tight junction genes, and cell morphology was investigated using a dextran sulfate sodium (DSS)-induced ulcerative colitis Caco-2 cell model. Treatment with fexuprazan, esomeprazole, tegoprazan, and vonoprazan significantly increased TEER values in a 3 % DSS-induced ulcerative colitis Caco-2 cells in a concentration-dependent manner. The TEER value-concentration profile showed sigmoidal shape curves and yielded half maximal effective concentration of 0.983 - 1.17 μg/mL for P-CABs and 3.27 μg/mL for esomeprazole. Among these drugs, fexuprazan showed the highest activity in the restoring intestinal barrier function. Fexuprazan also increased the expression of tight junction genes including zonula occludens-1, claudin 1, occludin, and mucin 1, and also thickened the epithelial cell membrane after treatment with 20 μg/mL fexuprazan. Fexuprazan showed a particularly high distribution in the liver and gastrointestinal tract in rats following oral administration of 2 mg/kg fexuprazan, which appears to be a positive characteristic of fexuprazan's effect on ulcerative colitis and gastric acid-related diseases although in vivo therapeutic efficacy of fexuprazan for ulcerative colitis requires further validation in both animal and human. In conclusion, fexuprazan can potentially restore intestinal barrier function by increasing the expression of tight junction genes and by strengthening the cell membrane integrity in DSS-induced colitis model.

2025-05-01·AMERICAN JOURNAL OF GASTROENTEROLOGY

The Role of P-CABs in GERD

Review

作者: Howden, Colin W.

Potassium-competitive acid blockers (P-CABs) constitute a relatively new class of gastric acid-suppressing drugs. Among this class, vonoprazan is the first to have been approved in the United States. However, some P-CABs including vonoprazan, tegoprazan, and fexuprazan have been available in other countries since at least 2014. The first aim of this article is to review pharmacological differences between P-CABs that are currently approved or in development with proton pump inhibitors. The specific focus thereafter is on the likely role of P-CABs in the treatment of different manifestations of gastroesophageal reflux disease. Multiple clinical trials have compared P-CABs with proton pump inhibitors in erosive esophagitis. Additional trials have compared P-CABs with placebo in nonerosive reflux disease. Relevant results are reviewed, and inferences are drawn for their use in the United States. Finally, consideration is given to additional, potential uses of P-CABs in the broader spectrum of gastroesophageal reflux disease, and some suggestions are made for future research initiatives.

项与盐酸非苏拉赞相关的新闻（医药）

2025-06-11

·PRNewswire

Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics

- The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug discovery programs for the generation of small molecule drugs. SEOUL, South Korea, June 11, 2025 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Daewoong Pharmaceutical Co., Ltd. Daewoong Pharmaceutical gains access to Salipro Biotech's expertise and Salipro® platform for stabilizing challenging membrane proteins (e.g., GPCRs, ion channels, transporters). The collaboration will target a specific membrane protein to aid Daewoong's development of novel small molecule drugs. Continue Reading Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics Under the terms of this agreement, the collaboration will enable Daewoong Pharma to leverage Salipro Biotech´s expertise and proprietary platform to advance their drug discovery efforts in the development of novel therapeutic small molecules against a challenging membrane protein drug target. "We are excited to join forces with Daewoong Pharmaceutical and contribute with our proprietary Salipro® platform to accelerate the development of novel therapeutic drugs for Daewoong Pharmaceutical's pipeline", said Jens Frauenfeld, CEO of Salipro Biotech. "This partnership is particularly significant as it marks our first collaboration with a partner in South Korea, underscoring the global application and versatility of our expertise and platform to make the undruggable druggable." Seongsoo Park, CEO at Daewoong Pharmaceutical stated, "Collaborating with Salipro Biotech and accessing their Salipro® platform aligns with our goal to address complex drug targets. Salipro's expertise in membrane protein stabilization will benefit our research for novel small molecule therapeutics, and we look forward to the results of our joint efforts." About Salipro Biotech AB Salipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro® platform technology for the stabilization of membrane proteins. The majority of drug targets are so-called membrane proteins; however, these targets are inherently unstable and challenging to investigate. The proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies, small molecule drugs and structure-based drug design. To date, Salipro Biotech has signed multiple research collaborations with top-tier pharma and biotech companies. Through in-house and partnered pipelines, Salipro Biotech AB accelerates the discovery of novel drugs. About Daewoong Pharmaceutical Daewoong Pharmaceutical (KRX: 069620.KS), established in 1945, is a global pharmaceutical company based in South Korea. The company is committed to the development, manufacturing, and commercialization of pharmaceutical products, with a mission to provide the most beneficial total solutions, including pharmaceuticals and services, which contribute to improving the quality of life of valued consumers. Operating with a keen focus on both domestic and international markets, Daewoong Pharmaceutical specializes in developing treatments for intractable and rare diseases. The company's diverse portfolio encompasses novel drugs, biologics, new products, and C&D, all supported by in-house research and development, open collaboration, and advanced manufacturing facilities. Marking significant achievements in drug development, Daewoong Pharmaceutical has successfully developed novel drugs for GERD, featuring the active ingredient Fexuprazan, and for Type 2 diabetes, with the active ingredient Enavogliflozin, in two consecutive years. The company is currently advancing in the development of First-in-Class Oral Anti-Fibrotic Agent for Idiopathic Pulmonary Fibrosis, utilizing Bersiporocin as a PRS Inhibitor. Notably, Bersiporocin has been designated by the U.S. FDA as an orphan drug and a Fast Track development product. SOURCE Daewoong Pharmaceutical Co., Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

孤儿药快速通道

2025-04-17

·摩熵医药

P-CAB市场三强争霸！科伦、扬子江等56家药企竞逐伏诺拉生仿制

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。新型抑酸药——钾离子竞争性酸阻滞剂(P-CAB)领域，武田的伏诺拉生以7.3亿元销售额领跑，罗欣药业的替戈拉生、柯菲平医药的凯普拉生紧随其后，三者均通过医保加速放量。仿制药企业如新时代药业、科伦药业已布局伏诺拉生首仿，2026年专利到期后市场或迎井喷。此外，上海医药的信诺拉生、扬子江的非苏拉生即将上市，P-CAB研发持续升温。然而，长期抑酸导致的感染、骨质疏松等风险仍需关注。本文基于摩熵咨询《H2受体阻滞剂K＋竞争性酸阻滞剂市场专题研究报告》，聚焦钾离子竞争性酸阻滞剂药物市场格局、企业策略与政策影响，解析未来竞争趋势。 01钾离子竞争性酸阻滞剂竞争格局：三足鼎立局面已形成截至2024年11月，我国已上市3款钾离子竞争性酸阻滞剂，分别是武田的伏诺拉生、罗欣药业的替戈拉生和柯菲平医药的凯普拉生。伏诺拉生是由武田制药研发，于2014年12月在日本获批上市，用于治疗胃溃疡、十二指肠溃、根除幽门螺旋杆菌、小剂量阿司匹林给药期间预防胃溃疡或十二指肠溃疡复发。2019年12月获批进入中国市场用于治疗反流性食管炎，其后在2023年11月获批与适当的抗菌药物联用以根除幽门螺杆菌。替戈拉生是罗欣药业与韩国HKinno.NCorporation通过合作协议，获得在中国境内独家研发、生产及商业化权益。2022年4月获批上市，用于治疗反流性食管炎。2023年11月获批用于十二指肠溃病，2024年获批与适当的抗菌药物联用以根除幽门螺杆菌。是我国首个获批三个适应症的钾离子竞争性酸阻滞剂。凯普拉生片是由柯菲平医药研发并由复兴医药独家商业化，2023年2月获批上市，用于十二指肠溃疡和反流性食管炎，又于2024年11月获批与适当的抗菌药物联用以根除幽门螺杆菌，是我国首款自主研发的钾离子竞争性酸阻滞剂。数据来源：摩熵医药数据库根据摩熵医药数据库统计显示，截至2024年11月，三款药物均已进入医保，处于放量阶段。富马酸伏诺拉生2020年通过谈判进入国家医保乙类目录（限反流性食管炎的患者），受益于医保放量，伏诺拉生销售额由2020年0.14亿元快速增长至2023年7.3亿元，年复合增长率达273.1%。替戈拉生片在2022年通过谈判进入国家医保乙类目录（限：1.十二指肠溃疡；2.反流性食管炎），销售额也在2023年突破1亿元。图片来源：摩熵咨询《H2受体阻滞剂K+竞争性酸阻滞剂市场研究专题报告》盐酸凯普拉生片在2023年通过谈判进入国家医保乙类目录（限反流性食管炎），长期放量值得期待。02伏诺拉生：国产仿制钾离子竞争性酸阻滞剂蓄势待发富马酸伏诺拉生的化合物专利预计于2026年8月29日到期，遵循专利法规定，仿制药市场需静待原研药专利失效。但各大领先药企早已未雨绸缪，新时代药业在2022年7月便捷足先登，夺得首仿桂冠，随后科伦药业、海汇药业、华森制药等企业紧跟步伐，市场迅速形成了“1+7”的竞争格局。此外，永太药业、康恩贝制药、万高药业等56家企业正翘首以待其产品上市审批的结果，而新华制药、北陆制药、白鹿药业等37家企业也已完成或正积极申报临床阶段，整个市场蓄势待发，竞争态势愈发紧张。图片来源：摩熵咨询《H2受体阻滞剂K+竞争性酸阻滞剂市场研究专题报告》03治疗与胃酸分泌相关疾病的药物市场趋势分析01钾离子竞争性酸阻滞剂创新药研发加速截至2024年11月，除了已上市的伏诺拉生、替戈拉生和凯普拉生外，还有两款钾离子竞争性酸阻滞剂即将上市，分别为上海医药的信诺拉生和扬子江的非苏拉生。2021年10月上海医药与贵州生诺生物及其全资子公司太瑞生诺签订《合作协议》，以不超过6.9亿元（除销售提成外）的交易金额取得X842项目（即信诺拉生酯胶囊）原料药及制剂在中国区域（包括中国香港、澳门及台湾地区）的独家委托生产和所有适应症的工业销售权。信诺拉生酯胶囊也于2023年2月申报上市，申报适应症为反流性食管炎。2023年6月，大熊制药与扬子江药业共同递交盐酸非苏拉生片的上市申请。盐酸非苏拉生片是大熊制药研发的一款新型钾离子竞争性酸阻滞剂类药物，扬子江药业及旗下海尼药业通过一项超20亿元的合作获得了其在中国的开发和销售权利。02长期应用抑酸剂带来的不良反应有待攻克抑酸剂出现为消化科治疗酸相关疾病带来革命性改变，但很多时候抑酸剂被用于了非适应症的患者。越来越多的研究报告抑酸制剂相关不良反应。抑酸剂相关不良反应最常见的是感染。其中的原因很好理解，即胃酸是我们胃内抵御外来微生物侵袭的第一道防线，当我们使用抑酸剂抑酸时，我们也就同时失去了胃内一线防御功能，无法抵御微生物的侵袭，经口摄入的微生物就会进入胃肠道从而引发感染。大量研究已经验证了抑酸剂与感染间的相关性。此外，也有研究报道了，抑酸剂长期应用导致的社区获得性肺炎或骨质疏松，以及代谢性疾病（例如：糖尿病），还有痴呆症。小结P-CAB领域，伏诺拉生、替戈拉生、凯普拉生均已纳入医保，伏诺拉生年复合增长率达273.1%，2023年销售额7.3亿元。武田原研药专利2026年到期，新时代药业等56家药企蓄势仿制，市场竞争白热化。信诺拉生、非苏拉生等新药即将上市，未来P-CAB赛道或迎爆发式增长，但长期抑酸的不良反应仍需攻克。END本文为原创文章，转载请留言获取授权H2受体阻滞剂钾离子竞争性酸阻滞剂市场研究专题报告完整报告领取方式近期热门资源获取CGT产业现状与未来趋势蓝皮书-202406中药行业现状与未来趋势白皮书-2024072023年医药企业综合实力排行榜-202408跨越国界，引领创新：中国药企出海的布局实践-202408专利即将到期五大重磅小分子药品，国内仿制药“战况”几何?-202409中国放射性药物市场现状分析报告-202410合成生物产业发展前景及中国合成生物产业链上中下游企业分析-202410中国合成生物学创投市场分析报告-202410中国糖尿病临床诊疗与药物多渠道市场数据分析-202411基于剂型改良的复杂注射剂分析--微球篇-2024112024医美注射材料市场发展分析报告-20241213国家药品集采跟踪报告-前9批次集采回顾与展望-202411近期更多摩熵咨询热门报告，识别下方二维码领取联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作👆👆👆点击上方图片，即可开启摩熵化学数据查询点击阅读原文，申请摩熵医药企业版免费试用！

专利到期上市批准

2025-04-09

·药筛

抑酸药市场的下一战

消化系统用药中，抑酸药是大品种的摇篮。早期的H2受体拮抗剂，西咪替丁、雷尼替丁、法莫替丁都是当年的热销品种。后来，质子泵抑制剂上市，凭借绝对碾压的疗效优势，很快就成为市场主导，诞生了奥美拉唑、艾司奥美拉唑、兰索拉唑等全球重磅药品。特别是在国内市场，多个PPI类药物百花齐放，撑起将近400亿市场规模，培育了罗欣、奥赛康、扬子江、丽珠等专注PPI类药物的企业。数据来源：摩熵医药然而，随着国采不断推进，主流PPI类药物陆续被国采，仿制药价格大幅下降，注射剂单价从50多元，下降到个位数，口服剂型也只剩几毛钱一片，整体市场缩水一半。奥美拉唑、泮托拉唑、兰索拉唑、艾司奥美拉唑等，逐步从医院畅销药榜单中消失。质子泵抑制剂医院市场TOP10排名，2024年H1相比2018年，已彻底换了个样。数据来源：摩熵医药相关企业排名方面，丽珠凭借艾普拉唑的强劲表现，2024年H1医院市场销售，断层式遥遥领先。数据来源：摩熵医药在集采政策影响下，抑酸药市场，已经风光不再，但面对巨大的市场规模，企业不会轻言退出。于是，大家发起了新一轮的市场争夺战。首先是H2拮抗剂药物。准入属性完美的法莫替丁、雷尼替丁，还有非医保的罗沙替丁，抓住政策空档期，老树发新芽，销售额暴涨，成就了一批企业和代理商。数据来源：摩熵医药不过随着罗沙替丁被国采，法莫替丁多家企业过评，国采在即，外加全国价格治理，这一波市场热度，预计很快就会消退。其次是PPI类复方制剂拉唑类单方口服制剂太卷，就有企业就开发复方制剂。最早获批的是奥美拉唑碳酸氢钠胶囊，此后又有奥美拉唑碳酸氢钠干混悬、兰索拉唑碳酸氢钠胶囊、艾司奥美拉唑碳酸氢钠胶囊获批。但是，受医保准入以及适应症限制，此类产品的总销售额在2021年达到高峰后，就开始下降，2023年医院市场不足1亿元，这在巨大的抑酸药市场里，已无足轻重。数据来源：摩熵医药第三个是PPI的异构体艾司奥美拉唑剔除了奥美拉唑的R型异构体，只保留S型异构体，取得了巨大成功。于是，其它PPI也可以如法炮制。右旋兰索拉唑和左旋泮托拉唑就是国内企业的重点开发目标。2022年，南京优科的注射用右兰索拉唑首家获批，2024年奥赛康第二家获批，产品也通过国谈进入医保，但由于价格较低，市场销售并不理想，2024年上半年，医院市场销售不足600万元，未来增长潜力有限。而左旋泮托拉唑，虽有企业提交上市申请，但此产品还需要三期临床，离产品获批上市还有较长时间。数据来源：摩熵药筛小程序最后，有钱的企业，都来卷P-CAB抑制剂。P-CAB抑制剂也就是钾离子竞争性酸阻滞剂，作用机制为竞争性结合壁细胞内H+/K+-ATP酶（质子泵）的钾离子结合部位，阻止胃酸分泌。相比拉唑类PPI药物，疗效上略有优势。国内已有多个企业，瞄准了这类产品。伏诺拉生伏诺拉生是全球首个上市P-CAB抑制剂，由武田和大冢联合开发，2015年最早在日本获批，2019年获批进口，2020年进入医保后快速放量，2023年医院市场销售额已超过6亿元。数据来源：摩熵药筛小程序国内仿制药企业快速跟进，一拥而上，目前已有10多个仿制获批，还有140多个上市申请处在审评中。可以想象，等到2026年原研专利到期，市场竞争会是什么格局！数据来源：摩熵药筛小程序需要关注的是，在今年3月，柯菲平独家提交了注射液2类新药上市申请，这个要是能获批，倒是非常有竞争力。数据来源：摩熵药筛小程序替戈拉生2015年，罗欣从韩国的HK inno.N公司，买了替戈拉生片的国内市场开发权益，2022年获批上市，当年就通过医保谈判。2024年上半年医院市场销售超过1亿元。凯普拉生凯普拉生片是有柯菲平开发，销售权给了复星医药，2023年2月获批上市，市场销售刚刚起步。利那拉生2024年12月，上海生诺的戊二酸利那拉生酯胶囊获批上市。这个品种是贵州生诺医药从瑞典的Cinclus Pharma引进，后来又卖给了上海医药。获批适应症是反流性食管炎，市场也刚刚起步。另外扬子江药业买了韩国大熊的非苏拉生片，2023年报产，预计很快也能获批。丽珠买了韩国Onconic的Zastaprazan（又名为JP-1366），目前还在三期临床中。未来，P-CAB抑制剂必将是抑酸药的主战场。用摩熵药筛小程序，随时查询新产品！

临床3期核酸药物申请上市医药出海

100 项与盐酸非苏拉赞相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16078

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
消化性溃疡	韩国	Daewoong Pharmaceutical Co., Ltd.	2025-05-12
胃食管反流	韩国	Daewoong Pharmaceutical Co., Ltd.	2021-12-30

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
幽门螺杆菌感染	临床3期	美国	Daewoong Pharmaceutical Co., Ltd.	2024-02-06
反流性食管炎	临床3期	中国	Daewoong Pharmaceutical Co., Ltd.	2021-12-30
胃炎	临床3期	美国	Daewoong Pharmaceutical Co., Ltd.	2020-06-02
非糜烂性胃食管反流病	临床3期	美国	Daewoong Pharmaceutical Co., Ltd.	2019-02-07
非糜烂性反流病	临床3期	美国	Daewoong Pharmaceutical Co., Ltd.	2019-02-07
糜烂性食管炎	临床3期	美国	Daewoong Pharmaceutical Co., Ltd.	2018-12-13
糜烂性胃食管反流病	临床3期	美国	Daewoong Pharmaceutical Co., Ltd.	2018-12-13
胃溃疡	临床1期	韩国	Daewoong Pharmaceutical Co., Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


UEGW2024	N/A	-	-	Fexuprazan 40 mg	醖夢獵選衊積淵夢範艱(築鬱艱願繭鹽糧夢範鹽) = 簾鏇鹽壓鬱簾網壓網鹽鏇構醖餘顧鬱繭願廠醖 (製窪積簾齋廠顧餘蓋範, -2.80 ~ 9.23) 更多	-	2024-10-13
				Esomeprazole 40 mg	醖夢獵選衊積淵夢範艱(築鬱艱願繭鹽糧夢範鹽) = 艱壓鹽願襯醖壓顧鹹鬱鏇構醖餘顧鬱繭願廠醖 (製窪積簾齋廠顧餘蓋範, -2.80 ~ 9.23) 更多
NCT05813561 (Pubmed) 人工标引	临床3期	糜烂性食管炎	332	Fexuprazan 40 mg	廠衊壓鹽齋觸壓醖積糧(願蓋餘鹹繭選鑰顧淵鏇) = 鬱築壓獵鹽衊壓糧積鬱遞積糧築壓願衊積鏇齋 (選鬱鹹繭獵膚窪鹽簾鬱 ) 更多	积极	2024-01-22
				Esomeprazole 40 mg	廠衊壓鹽齋觸壓醖積糧(願蓋餘鹹繭選鑰顧淵鏇) = 願鹽鏇獵壓鹽鏇鹽築積遞積糧築壓願衊積鏇齋 (選鬱鹹繭獵膚窪鹽簾鬱 ) 更多
NCT04341454 (Pubmed \| Gut Liver)	临床3期	急性胃炎 \| 慢性胃炎	327	Fexuprazan 20 mg q.d.	獵衊築願構願膚蓋鹹鏇(觸獵製衊餘鹹構鏇築鏇) = 繭積鬱醖鑰築膚網觸憲鏇鹹鏇觸顧鑰憲繭淵夢 (糧願夢鑰淵築鑰艱醖範 )	-	2023-02-15
				Fexuprazan 10 mg b.i.d.	獵衊築願構願膚蓋鹹鏇(觸獵製衊餘鹹構鏇築鏇) = 廠遞夢觸繭膚願鑰積壓鏇鹹鏇觸顧鑰憲繭淵夢 (糧願夢鑰淵築鑰艱醖範 )
UEGW2022	N/A	急性胃炎 \| 慢性胃炎	-	Fexuprazan 20 mg q.d.	蓋廠顧憲夢構餘簾簾積(網顧願廠淵糧構齋願膚) = 襯簾構鏇繭鏇鑰鹽遞鹹膚選觸窪積築觸膚夢獵 (鏇遞壓襯蓋積鹽選壓憲 )	-	2022-10-09
				Fexuprazan 10 mg b.i.d.	蓋廠顧憲夢構餘簾簾積(網顧願廠淵糧構齋願膚) = 廠淵鑰淵觸壓壓衊鏇艱膚選觸窪積築觸膚夢獵 (鏇遞壓襯蓋積鹽選壓憲 )
NCT03574415 (Pubmed \| Aliment Pharmacol Ther) 人工标引	临床1期	-	80	DWP14012	夢選鏇窪醖鏇範淵獵蓋(襯齋壓簾廠繭衊積憲鏇) = the mean percentages of time that the intragastric pH was above 4 after multiple doses of 40 mg in the Korean, Caucasian and Japanese subjects were 64.3%, 62.8% and 70.3%, respectively, and the corresponding values for the 80 mg dose were 94.8%, 90.6% and 90.6% respectively. 網憲憲夢窪壓鏇鏇夢積 (餘餘糧範膚鏇鹽獵膚鏇 )	积极	2020-12-01
				Placebo
NCT03736369 (Biospace) 人工标引	临床3期	胃食管反流	263	Fexuprazan	積網繭醖壓選網遞襯襯(繭餘衊壓夢鹹夢積蓋淵) = 顧廠鹹範蓋廠製鏇憲繭憲範鬱顧繭餘觸顧壓製 (糧積鹽膚襯鏇餘範膚積 )	非劣	2020-05-08
				Esomeprazole Magnesium	積網繭醖壓選網遞襯襯(繭餘衊壓夢鹹夢積蓋淵) = 憲範鹹築觸憲簾廠鏇遞憲範鬱顧繭餘觸顧壓製 (糧積鹽膚襯鏇餘範膚積 )